| Oxaliplatin-induced neurotoxicity is dependent on the organic cation transporter OCT2 JA Sprowl, G Ciarimboli, CS Lancaster, H Giovinazzo, AA Gibson, G Du, ... Proceedings of the National Academy of Sciences 110 (27), 11199-11204, 2013 | 195 | 2013 |
| Proximal tubular secretion of creatinine by organic cation transporter OCT2 in cancer patients G Ciarimboli, CS Lancaster, E Schlatter, RM Franke, JA Sprowl, ... Clinical Cancer Research 18 (4), 1101-1108, 2012 | 166 | 2012 |
| A phosphotyrosine switch regulates organic cation transporters JA Sprowl, SS Ong, AA Gibson, S Hu, G Du, W Lin, L Li, S Bharill, ... Nature communications 7 (1), 10880, 2016 | 125 | 2016 |
| CYP3A4*22 Genotype and Systemic Exposure Affect Paclitaxel-Induced Neurotoxicity AJM de Graan, L Elens, JA Sprowl, A Sparreboom, LE Friberg, ... Clinical Cancer Research 19 (12), 3316-3324, 2013 | 111 | 2013 |
| Conjunctive therapy of cisplatin with the OCT2 inhibitor cimetidine: influence on antitumor efficacy and systemic clearance JA Sprowl, L van Doorn, S Hu, L Van Gerven, P de Bruijn, L Li, AA Gibson, ... Clinical Pharmacology & Therapeutics 94 (5), 585-592, 2013 | 106 | 2013 |
| Disease‐associated changes in drug transporters may impact the pharmacokinetics and/or toxicity of drugs: a white paper from the International Transporter Consortium R Evers, M Piquette‐Miller, JW Polli, FGM Russel, JA Sprowl, K Tohyama, ... Clinical Pharmacology & Therapeutics 104 (5), 900-915, 2018 | 104 | 2018 |
| Role of aldo-keto reductases and other doxorubicin pharmacokinetic genes in doxorubicin resistance, DNA binding, and subcellular localization AD Heibein, B Guo, JA Sprowl, DA MacLean, AM Parissenti BMC cancer 12, 1-14, 2012 | 100 | 2012 |
| Mitigation of acute kidney injury by cell-cycle inhibitors that suppress both CDK4/6 and OCT2 functions N Pabla, AA Gibson, M Buege, SS Ong, L Li, S Hu, G Du, JA Sprowl, ... Proceedings of the National Academy of Sciences 112 (16), 5231-5236, 2015 | 99 | 2015 |
| Alterations in tumor necrosis factor signaling pathways are associated with cytotoxicity and resistance to taxanes: a study in isogenic resistant tumor cells JA Sprowl, K Reed, SR Armstrong, C Lanner, B Guo, I Kalatskaya, L Stein, ... Breast Cancer Research 14, 1-18, 2012 | 76 | 2012 |
| Human OCT2 variant c.808G>T confers protection effect against cisplatin-induced ototoxicity C Lanvers-Kaminsky, JA Sprowl, I Malath, D Deuster, M Eveslage, ... Pharmacogenomics 16 (4), 323-332, 2015 | 74 | 2015 |
| Modulation of OATP1B-type transporter function alters cellular uptake and disposition of platinum chemotherapeutics CS Lancaster, JA Sprowl, AL Walker, S Hu, AA Gibson, A Sparreboom Molecular cancer therapeutics 12 (8), 1537-1544, 2013 | 70 | 2013 |
| Cisplatin-induced renal injury is independently mediated by OCT2 and p53 JA Sprowl, CS Lancaster, N Pabla, E Hermann, AM Kosloske, AA Gibson, ... Clinical Cancer Research 20 (15), 4026-4035, 2014 | 69 | 2014 |
| The temporal relationship between ABCB1 promoter hypomethylation, ABCB1 expression and acquisition of drug resistance K Reed, SL Hembruff, JA Sprowl, AM Parissenti The pharmacogenomics journal 10 (6), 489-504, 2010 | 69 | 2010 |
| OATP1B2 deficiency protects against paclitaxel-induced neurotoxicity AF Leblanc, JA Sprowl, P Alberti, A Chiorazzi, WD Arnold, AA Gibson, ... The Journal of clinical investigation 128 (2), 816-825, 2018 | 68 | 2018 |
| Polymorphic transporters and platinum pharmacodynamics JA Sprowl, RA Ness, A Sparreboom Drug metabolism and pharmacokinetics 28 (1), 19-27, 2013 | 65 | 2013 |
| Neuronal uptake transporters contribute to oxaliplatin neurotoxicity in mice KM Huang, AF Leblanc, ME Uddin, JY Kim, M Chen, ED Eisenmann, ... The Journal of clinical investigation 130 (9), 4601-4606, 2020 | 54 | 2020 |
| Identification of OAT1/OAT3 as contributors to cisplatin toxicity S Hu, AF Leblanc, AA Gibson, KW Hong, JY Kim, LJ Janke, L Li, ... Clinical and translational science 10 (5), 412-420, 2017 | 51 | 2017 |
| Regulation of drug transport proteins—From mechanisms to clinical impact: A white paper on behalf of the international transporter consortium KLR Brouwer, R Evers, E Hayden, S Hu, CY Li, ... Clinical Pharmacology & Therapeutics 112 (3), 461-484, 2022 | 37 | 2022 |
| Uptake carriers and oncology drug safety JA Sprowl, A Sparreboom Drug Metabolism and Disposition 42 (4), 611-622, 2014 | 37 | 2014 |
| Associations Between ABCC2 Polymorphisms and Cisplatin Disposition and Efficacy JA Sprowl, V Gregorc, C Lazzari, RH Mathijssen, WJ Loos, A Sparreboom Clinical Pharmacology & Therapeutics 91 (6), 1022-1026, 2012 | 35 | 2012 |
